Cholangiocytes are the target cells in chronic cholestatic liver diseases such as primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), which are characterized by the damage, proliferation and differentiation of cholangiocytes of different sizes (i.e., small and large). Cholangiocyte differentiation and biliar remodeling are critical for the maintenance of biliary mass and the functional recovery during the pathogenesis of these devastating liver diseases. The elucidation of the intracellular mechanisms regulating the differential regenerative responses of small and large cholangiocytes to cholestasis and liver injury/toxins will play a pivotal role in the development o therapeutic strategies for the treatment of cholestatic liver diseases. During chronic hepatobiliary injury, a population of bipotent liver progenitor cells becomes activated to replenis both cholangiocytes and hepatocytes. If small cholangiocytes with multipotential capacity exist within human and rodent bile ducts, these cells should possess the ability to differentiate into either large cholangiocytes or hepatocytes during liver damage, such as diseased conditions in which large cholangiocytes or hepatocytes are lost or regenerative mechanisms are hampered. The plasticity of intrahepatic cholangiocytes has been postulated that terminally differentiated cells of one lineage may directly differentiate into another lineage or undergo trans-differentiation. Therefore, specific subpopulations of cells, such as small cholangiocytes that express known biliary progenitor cell markers, can be hypothesized to contain a multipotent cell population when exposed to certain pathological conditions. We propose the central hypothesis that small cholangiocytes contribute to the recovery of biliary injury through acquiring the phenotypes of liver progenitor cells and large cholangiocytes under diseased conditions. Systematic investigation of pluripotent genes and microRNAs is proposed in this application as markers in small cholangiocytes with the therapeutic potentials for cholestatic liver injury. The central hypothesis will be evaluated by three specific aims. First, we will distinguish pluripotent functional signaling pathways involved in tissue repair-related cellular functions in small and large cholangiocytes. Second, we will identify TGF-? dependent miRNAs involved in differentiation/regeneration-related cellular functions in small cholangiocytes. Last, we will determine the effects of small cholangiocytes and their-associated miRNAs on accelerating the morphologic and functional recovery of transgenic and chronic cholestatic liver injury in specific animal models. Therapeutic effects of cell engraft/miRNA manipulation on biliary cell growth and differentiation will be evaluated in vivo. Novel insights into the physiological roles and mechanisms of molecular and functional heterogeneity in human biliary epithelium will be obtained. Meanwhile, the fundamental knowledge obtained in the regulation of growth, differentiation and remodeling by small cholangiocytes/biliary committed progenitors is expected to advance the field of cholangiocyte biology/ pathophysiology.

Public Health Relevance

Bile duct cells have extensive reconstruction potential for impacting human health, and the health relatedness of this grant proposal is that effective treatments are lacking for chronic cholestatic liver diseases, such as primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Chronic cholestatic liver diseases cause damage/growth/reconstruction of bile ducts in the liver. The rationale for our research is that the successful completion of the studies can ultimately be expected to provide a greater understanding of cholestatic liver disease progression/recovery and increase opportunities for the development of novel treatment paradigms for the management of chronic liver diseases.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Doo, Edward
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Texas A&M University
Internal Medicine/Medicine
Schools of Medicine
College Station
United States
Zip Code
Martínez, Allyson K; Maroni, Luca; Marzioni, Marco et al. (2014) Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies. Curr Pathobiol Rep 2:143-153
Francis, Heather; McDaniel, Kelly; Han, Yuyan et al. (2014) Regulation of the extrinsic apoptotic pathway by microRNA-21 in alcoholic liver injury. J Biol Chem 289:27526-39
Lleo, Ana; Maroni, Luca; Glaser, Shannon et al. (2014) Role of cholangiocytes in primary biliary cirrhosis. Semin Liver Dis 34:273-84
De Minicis, Samuele; Kisseleva, Tatiana; Francis, Heather et al. (2013) Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis 45:450-9
Jensen, Kendal Jay; Alpini, Gianfranco; Glaser, Shannon (2013) Hepatic nervous system and neurobiology of the liver. Compr Physiol 3:655-65
Meng, Fanyin; Francis, Heather; Glaser, Shannon et al. (2012) Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration. Hepatology 55:209-21
Jensen, Kendal; Marzioni, Marco; Munshi, Kamruzzaman et al. (2012) Autocrine regulation of biliary pathology by activated cholangiocytes. Am J Physiol Gastrointest Liver Physiol 302:G473-83
Francis, Heather L; Demorrow, Sharon; Franchitto, Antonio et al. (2012) Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms. Lab Invest 92:282-94
Meng, Fanyin; Glaser, Shannon S; Francis, Heather et al. (2012) Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med 16:160-73
Francis, Heather; Meng, Fanyin; Gaudio, Eugenio et al. (2012) Histamine regulation of biliary proliferation. J Hepatol 56:1204-6

Showing the most recent 10 out of 34 publications